We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Roquefort Therapeutics Plc | LSE:ROQ | London | Ordinary Share | GB00BMDQ2T15 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 3.57% | 4.35 | 4.20 | 4.50 | 4.35 | 4.10 | 4.20 | 940,202 | 11:07:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Cmp Integrated Sys Design | 200k | -1.75M | -0.0135 | -3.22 | 5.42M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/4/2024 14:08 | Lets not forget recent news Midkine mRNA Program MilestoneFurther to the announcement on 6 February 2024, where Roquefort Therapeutics announced that its mRNA therapeutics were undergoing studies in combination with proprietary lipid nanoparticle (LNP) delivery systems, the Company has continued development in validated in vivo models. These latest experiments combined the mRNA with a LNP delivery system in a validated in vivo model of liver cancer and demonstrated the safety and efficacy in reducing functional Midkine of the novel mRNA LNP combination. This represents a significant milestone in both the discovery of a novel mRNA therapeutic and in the safe combination with an LNP to allow for the delivery of the mRNA as an anti-cancer medicine. Liver cancer is a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year[1]. Midkine is associated with liver cancer progression, resistance and prognosis[2]. A novel therapeutic that targets Midkine expressing liver cancers with the cutting-edge mRNA technology offers the potential for a first-in-class medicine in the $3B liver cancer market. STAT-6 siRNA Program MilestoneOn 7 August 2023 the Company announced that it had developed four additional siRNA sequences that attack the target STAT-6 (Signal Transducer and Activator of Transcription) and its SH2 (Src-homology-2) domain. The Company has continued the development of these novel STAT-6 medicines in validated in vitro models of colon cancer with the results demonstrating efficacy of the four new siRNA sequences in reducing STAT-6 expression by 40-50%. | lookinggood | |
05/4/2024 14:05 | This is a good buy price now really. The company could have a deal land any day as they are working on this. | lookinggood | |
05/4/2024 14:04 | Lse people were shouting holders were selling, lse members were shouting placing, twitter were claiming placings, or bad news, advf was claiming placingsShorters prob jumped on itCompany are not doing a placing now so all good | lookinggood | |
05/4/2024 13:20 | Your an embarrassment | tomzimerman | |
05/4/2024 12:57 | Only if he's on the insiders list... otherwise he/she can argue word of mouth, rumours etc | epifanio1 | |
05/4/2024 12:02 | Ouch. I would NOT like to be Phil453 right now!!! If he didn't use a VPN to set up both his ADVFN and email accounts, he's in big trouble. | bozzy_s | |
05/4/2024 07:37 | That news is even worse than a placing... they still need cash, next stop death spiral finance shop.... | epifanio1 | |
05/4/2024 07:08 | chaps you really think a guy on advfn moved it? come on now | stockhunters | |
05/4/2024 06:42 | Response to Share Price Movement Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, notes recent bulletin board speculation about a placing that the Company may be undertaking. The Company recently engaged its advisers to commence a process of market soundings in relation to a potential fundraise. However, in response to incorrect bulletin board comments regarding a speculative placing price and resulting unusual share price movements, the Board has decided to not proceed with any potential placing at this time. As previously announced, Roquefort Therapeutics remains focused on completing an out-licensing agreement during the course of 2024 with potential Big Pharma partners and will update the market when a binding agreement is entered into. | apotheki | |
05/4/2024 06:41 | See todays RNS setting the record straight.It is a sad situation when BB misuse necessitates such action. | oldtimer169 | |
04/4/2024 17:49 | Phil453 Only joined yesterday #wan*er | mildredgallon | |
04/4/2024 17:44 | You're done!!!! | turbotrader2 | |
04/4/2024 17:44 | Criminal and he's been reported to the FCABE WARNED | turbotrader2 | |
04/4/2024 17:40 | Probably a dirty scammer to get price down to buy in | mildredgallon | |
04/4/2024 16:49 | I'm interested in whether the 2p placing 'insider' is a criminal, or a lying scammer. There have been some shocking placing prices in the last few months, so wouldn't be surprised if it's true. | bozzy_s | |
04/4/2024 13:41 | Deal mode roqsuckers | shortcpx |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions